Efficacy of Ranolazine in reduction of blood sugar in type 2 diabetic patients with ischemic heart disease

Efficacy and safety endpoints of Ranolazine in comparison with conventional therapy in reduction of HbA1c percentage in type 2 diabetic patients with ischemic heart disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161026030511N3

Enrollment

Registered

2018-12-23

Start date

2016-06-21

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Diabetes mellitus. Condition 2: Stable angina. Type 2 diabetes mellitus with hyperosmolarity Other forms of angina pectoris

Interventions

Intervention 1: intervention group: treatment with Ranolazine (Ranexa) 1000 mg orally 2 times a day for 8 weeks. Intervention 2: Control group: continued their conventional therapy Nitroglycerin 2.6 m

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: HbA1c more than 6.5%, Age more than 50 year, both genders with diabetes mellitus and coronary artery disease (CAD) Experiencing chronic stable angina for at least 3 months triggered by physical effort and relieved by rest and/or sublingual nitroglycerin CAD documented by one or more of the following: Angiography evidence of more than 50% stenosis of one or more coronary arteries, History of MI, cardiac imaging or exercise test diagnostic for CAD Treatment with up to 2 anti-anginal therapies at a stable dose for at least 2 weeks before starting the trial T2DM patients who use Metformin and Gliclazide

Exclusion criteria

Exclusion criteria: New York Heart Association class III and IV Acute coronary syndrome in the prior 2 months or planned for coronary revascularization Stroke or transient ischemic attack within 6 months prior QTc more than 500 ms Systolic blood pressure more than 180, diastolic blood pressure more than 110 mmHg Liver cirrhosis Prior treatment with CYP 3A4 inhibitors or P GlyP inductors Treatment with anti arrhythmic medicine class ll and lll Alcohol consumption or drug users Simvastatin consumption

Design outcomes

Primary

Measure	Time frame
Percentage of HbA1c. Timepoint: Per month. Method of measurement: Blood test Hitachi 911 automatic analyzer.	—

Secondary

Measure	Time frame
Reduction of using sublingual nitroglycerin per week. Timepoint: Weekly. Method of measurement: Patient report.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahram Fariborz Farsad

Rajaie cardiovascular, medical and research center

ffarsad@yahoo.com+98 21 2266 3310

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026